Case Study 3: Zepbound (GLP-1 Agonist) for Type 2 Diabetes/Obesity
Patient: 48-year-old female with type 2 diabetes and obesity, started on Zepbound (tirzepatide) 2.5 mg SC weekly.
Q13. Highlight the assessment findings that are most concerning for a patient on Zepbound:
Q14. Which order should the nurse question?
Q15. Select all teaching points for Zepbound:
Q16. Place the following nursing actions in order of priority if the patient develops severe abdominal pain and vomiting:
--Select-- Hold medication Notify the provider Assess airway and vital signs Document findings
--Select-- Hold medication Notify the provider Assess airway and vital signs Document findings
--Select-- Hold medication Notify the provider Assess airway and vital signs Document findings
--Select-- Hold medication Notify the provider Assess airway and vital signs Document findings
Q17. Matrix: Indicate if each is a common or serious side effect of Zepbound:
Q18. Which finding requires immediate provider notification?